IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that Masimo is helping clinicians at Renown Health in Reno, Nevada, to address the COVID-19 surge, including through use of Masimo SafetyNet™, a remote patient management platform. Renown Health is using Masimo SafetyNet to help care for patients positive for COVID-19 recover at home—and to help notify clinicians of the need to intervene when patients exhibit signs of deterioration.
Renown Health is a non-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. Masimo SafetyNet, introduced earlier this year as part of Masimo’s efforts to help hospitals and clinicians combat the pandemic, is now in use at numerous institutions around the world. Renown Health uses Masimo Patient SafetyNet™ and Masimo Rad-97® Pulse CO-Oximeters® to provide bedside and remote oxygen saturation and respiratory and pulse rate monitoring and notification within their hospitals and at a state-of-the-art 700-bed Alternate Care Facility. The facility has expanded into an adjacent parking structure, turned into a makeshift general ward to accommodate the unprecedented surge of patients suffering from COVID-19. In addition, Renown was one of the first systems to implement Masimo SafetyNet to expand patient care from the hospital to the home.
“We at Renown are proud of our national reputation as an innovator in implementing new models, technology, and systems of care for the community,” said Tony Slonim, MD, DrPH, President & CEO. “We are working with some incredible partners, including Masimo, to transform care and demonstrate value in a way that appeals to patients and helps clinicians improve outcomes and reduce costs. Renown’s Hospital-at-Home model of care technology enables patients to receive hospital-level care in the comfort of their own homes. This is especially critical for patients who are elderly, frail or vulnerable to complications.”
“This type of technology is a game-changer in improving patient care,” said Paul Sierzenski, MD, MSHQS, Chief Medical Officer, Acute Services, Renown Health. “Given the demand on our hospitals during this COVID-19 pandemic, we are pleased to provide appropriate patients with this telehealth solution, which assists in our management of patients with COVID-19 and allows patients the convenience of being in their own homes.”
Renown has found particular benefit in using Masimo SafetyNet to spot possible deterioration in home-based patients’ vital signs and intervene proactively, before their condition worsens. Dr. David Lemak, Section Chief for Urgent Care at Renown Medical Group-Ryland St., heads the team which conducts virtual telehealth visits with discharged patients. Recently, they noticed several drops in the oxygen saturation of Jim Cox, a 58-year-old patient who was being monitored at home as he recovered from COVID-19. Following a virtual visit with Dr. Lemak, Jim returned to the hospital, where cardiac complications could be addressed.
“I was excited to be one of the first patients chosen to use the Masimo SafetyNet ‘hospital-at-home’ technology,” said Jim Cox of Reno. “The system was easy to use. I was able to monitor my own vital signs through the app on my cell phone, and was pleased with the virtual medical visits provided by Dr. Lemak, and the nurses monitoring my device. It was a relief to be back with my family, recuperating in my own bed and making my own meals.”
“With Masimo SafetyNet,” said Dr. Lemak, “we have access to continuous, meaningful data, without burdening our recovering patients, giving my team confidence that even when they’re not physically present with us, our patients are in good hands. We’re so grateful to have been able to help Jim—without this system, the outcome could have been very different.” Jim added, “While I was at home, my medical condition did not improve. Without this device and the Renown staff checking in with me, I probably would have ignored my symptoms and tried to sleep it off. Instead, I was immediately admitted back to the hospital.”
“Our patients at Renown have the most sophisticated and reliable respiratory monitoring available anywhere,” said Jason Farnsworth, MBA, Director of Respiratory Care Services at Renown. “We know that physiologic monitoring improves outcomes and saves lives. The ability to extend that capability to patients in non-traditional settings and at home during this crisis is transformative. Our teams are excited to be able to help patients and their families – and ensure they receive the clinical support they need by using this technology and monitoring.”
“To know that we can provide quality care for patients recovering from COVID-19, and help ease their transition back to their normal lives, where they can recover in the comfort of their own homes, is fantastic,” said Mitchell Fong, Director of Telehealth Services at Renown. “Patients have shared that they enjoy being at home, sitting in their favorite recliner, enjoying a home-cooked meal and even transitioning back to remote work. If we can help people feel better, we feel better.”
Joe Kiani, Founder and CEO of Masimo, said, “We are grateful to be able to partner with institutions like Renown Health to make a positive difference at this exceptionally difficult time. Like hospitals and doctors everywhere, Renown is doing their best to help as many patients as possible, and Masimo SafetyNet allows them to stretch their resources and keep much-in-demand in-hospital beds free for the most acute cases, without compromising their ability to keep track of lower-acuity patients efficiently and effectively at home. We look forward to continuing to collaborate with Renown Health in the future as we expand the ways that Masimo SafetyNet and our other monitoring and automation solutions can help Renown improve their patient care and outcomes.”
Harnessing its expertise in noninvasive patient monitoring, automation, and telehealth solutions, Masimo developed Masimo SafetyNet—which combines hospital-grade tetherless pulse oximetry, continuous temperature measurement, and a remote data capture and surveillance platform—to help hospitals accommodate surges in COVID-19 patient volume and help lower-acuity patients recover at home and in other alternate care spaces. Masimo SafetyNet allows clinicians to monitor their patients’ physiological status—including oxygen saturation, respiration rate, pulse rate, and temperature—from afar, at all times. Masimo SafetyNet can be rapidly deployed and easily scaled as needed, without additional hardware or network infrastructure, helping caregivers provide the best possible care during this pandemic.
@Masimo | #Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.9 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris Gateway®, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView: 60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SafetyNet™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo SafetyNet, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
About Renown Health
Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to continually improve the care and the health of our community. For more information, visit renown.org.